ABSTRACT
Background Chronic rhinosinusitis (CRS) is characterized by persistent nasal and paranasal sinus mucosa inflammation. It comprises two phenotypes, namely CRS with nasal polyps (CRSwNP) and without (CRSsNP). CRSwNP can be associated with asthma and hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) in a syndrome known as NSAID-exacerbated respiratory disease (N-ERD). Furthermore, CRS frequently intertwines with respiratory allergies.
Objective This study investigated the phenotypic characteristics of peripheral blood mononuclear cells (PBMCs) within cohorts of CRS patients, additionally examining the influence of comorbid respiratory allergies on these parameters.
Methods 24 participants were grouped into controls, CRSsNP, CRSwNP, and N-ERD (n=6/group), with half of the patients in each group having respiratory allergies. Levels of cytokines were quantified in nasal secretions and sera. The abundance and phenotypic features of immune cells in PBMCs were evaluated through mass cytometry and clustering methods.
Results N-ERD patients showed heightened type 2 nasal cytokine levels. Mass cytometry analysis revealed increased activated naive B cell levels in CRSwNP and N-ERD, while resting naive B cells were higher in CRSsNP. Th2a cell levels did not differ between CRS subtypes but were significantly elevated in allergic subjects. In CRSwNP and N-ERD patients, naive B cells had a lower CXCR5 and higher CD45RA expression, while NK cells displayed reduced CD56 levels.
Conclusions There are distinct immunological features in PBMCs of CRS phenotypes and allergy, characterized by elevated resting naive B cells in CRSsNP, increased activated naive B cells in CRSwNP and N-ERD, and higher Th2a cell levels in allergic subjects.
Capsule summary This study examines immunological profiles in different phenotypes of CRS with and without comorbid allergy patients, highlighting immune cell intricacies in CRS subtypes and immune differences in CRS and respiratory allergy.
Competing Interest Statement
SS served as a speaker and/or consultant and/or advisory board member for Sanofi, GSK, and Novartis. SS is an investigator for Novartis and AstraZeneca (grants paid to his institution). JED served as a speaker and/or consultant and/or advisory board member for Sanofi, Allergopharma, AstraZeneca, GSK, and Novartis. JED is an investigator for Novartis and AstraZeneca (grants paid to her institution).
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Committee of the Medical University of Vienna gave approval for this work (EK Nr. 1492/2023).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
ABBREVIATIONS
- CCL
- Chemokine (C-C Motif) Ligand
- CD
- Cluster of differentiation
- CRS
- Chronic rhinosinusitis
- CRSsNP
- Chronic rhinosinusitis without nasal polyps
- CRSwNP
- Chronic rhinosinusitis with nasal polyps
- CyTOF
- Cytometry by Time-Of-Flight
- G-CSF
- granulocyte-colony stimulating factor
- GM-CSF
- Granulocyte-macrophage colony-stimulating factor
- Ig
- Immunoglobulin
- IL
- Interleukin
- IFN
- Interferon
- MMI
- Median metal intensity
- NSAIDs
- Non-steroidal anti-inflammatory drugs
- N-ERD
- NSAIDs-exacerbated respiratory disease
- opt-SNE
- Optimized t-distributed stochastic neighbour embedding
- PBMC
- Peripheral blood mononuclear cells
- SNOT-20
- 20-item sinonasal outcome test
- TNF
- Tumour necrosis factor
- TSLP
- Thymic stromal lymphopoietin
- VEGF
- Vascular endothelial growth factor